Introduction
Asthma is characterized pathologically by inflammation of the airways, associated with epithelial fragility and thickening of the reticular basement membrane, which in turn are thought to give rise to the clinical features of the disease (variable airway obstruction and hyperresponsiveness to various stimuli). The pivotal role of inflammation in the pathogenesis of asthma provides theoretical justification for the use of inhaled corticosteriods, which are known to exert a potent anti-inflammatory effect. These agents are therefore considered first-line therapy for the most patients with asthma (1, 2) , in the belief that if chronic inflammation can be suppressed then the associated short-and long-term consequences could be prevented. However, the mechanisms by which inhaled corticosteroids exert their antiinflammatory activity are not fully understood. 0954-6111/OO/OFOOS16+O6 $35.00/O example, it remains unclear which components of the inflammatory process are first affected by these agents, and which are most sensitive in terms of response to treatment.
This review discusses the anti-inflammatory profile of inhaled corticosteroids, with a view to further understanding their mechanism of action, based on the findings of endobronchial biopsy studies in patients with asthma.
Review of biopsy studies EFFECT ON MAST CELLS AND EOSINOPHILS
It is well established that bronchial inflammation in asthma is characterized by increased numbers of mast cells, eosinophils and T-lymphocytes. Mast cells play an important role in the immediate asthmatic reaction to allergens (3), which is mediated by the release of powerful smooth muscle and vasoactive mediators such as histamine, prostaglandins and cysteinyl leukotrienes (4). Mast cell activation also leads to the release of chemoattractants for eosinophils; these cells release granular proteins (e.g. major basic protein and eosinophil cationic protein) that are toxic to the airway epithelium.
The number of mast cells, eosinophils and T lymphocytes (along with the extent of their activation) has therefore been a major focus of endobronchial biopsy assessment in studies of inhaled corticosteroids, as discussed below. Several inhaled corticosteroids are presently available, each of which has undergone evaluation in terms of endobronchial biopsy findings during treatment. For example, treatment with inhaled budesonide 800,~g twice daily was associated with a significant decrease in eosinophils in biopsy specimens from patients with mild asthma (5). A small placebo-controlled study of mildly asthmatic patients reported that 4 months of treatment with inhaled beclomethasone dipropionate (BDP) 500 pg twice daily led to significant reductions in the number of both mast cells and eosinophils, including the activated fraction (6). Hoshino et al. (7) also reported significant decreases in the number of activated eosinophils and mast cells in biopsy samples from patients treated with BDP for atopic asthma. These findings confirm the results of earlier studies, in which BDP significantly reduced the number of eosinophils in the epithelium and lamina propria of biopsy samples from asthmatic patients (8).
Fluticasone propionate (FP) is an inhaled corticosteroid that is highly effective in the treatment of asthma (9). Numerous studies have reported biopsy findings following treatment with this agent. In a placebo-controlled study of patients with mild asthma, for example, Li et al. reported that treatment for 6 weeks with inhaled FP 25Opg twice daily reduced the number of total eosinophils (EGl +) and mast cells by 53% and 29%, respectively (10). and mast cells (including the proportion of degranulated mast cells) in biopsy specimens, whereas placebo had no effect (Fig. 1) . Evidence for an anti-inflammatory effect of FP was strengthened by the reductions in levels of mediators and numbers of activated cells in bronchoalveolar lavage (12).
Although inhaled corticosteroids are effective in the treatment of asthma, there is some evidence of ongoing airway inflammation despite maintenance therapy (13) which suggests that some components of airway inflammation are less sensitive to inhaled corticosteroids.
The effect of inhaled FP on airway inflammation at the maximum recommended dosage of 1000 pg twice daily was recently investigated in two studies (14, 15 These authors used the technique of induced sputum, in which patients inhale nebulized hypertonic saline and are then encouraged to cough and expectorate sputum, to compare the effects of inhaled FP (at dosages of 500 and 200 pg day-') versus oral prednisolone (30mgday-') on airways inflammation. Overall, there was a dose-dependent reduction in eosinophil numbers and eosinophil cationic protein levels in sputum after 2 weeks of treatment with inhaled FP. At the higher FP dosage, these changes were similar to those observed for oral prednisolone (Fig. 2 ), and were accompanied by improvements in lung function and hyperresponsiveness that were significantly greater than those in the prednisolone group (16).
EFFECT ON T LYMPHOCYTES
The chronic airway inflammation in patients with asthma is also associated with prolonged residence in the bronchial wall of activated T-lymphocytes (17). These cells therefore represent further targets for therapeutic intervention, and the effect of inhaled corticosteroids on T-lymphocytes has been evaluated in several biopsy studies in asthmatic patients (10,14,15). For example, Faul et al. (15) reported that 8 weeks of treatment with inhaled FP (1000,ug twice daily) produced reductions in the number of T-lymphocytes and CD45RO+
T-lymphocytes in the bronchial wall within 2 weeks of commencing therapy. Given the concomitant profile of reductions in eosinophils over the &week treatment period (as described above), the authors speculated that the reduction in eosinophils occurred as a consequence of the initial decrease in the number of CD45RO+ T-lymphocytes in the mucosa. This is in accordance with the knowledge that T-cell-derived cyto-(4 Prednisolone Fluticasone propionate 2000,ugdaym' 500 pg day-' Ol-I kines, such as interleukin-5 and granulocyte macrophagecolony-stimulating factor (GM-CSF), are responsible for accumulation and prolonged survival of eosinophils in the airways (1819).
The primary mechanism of action of inhaled corticosteroids may therefore be to down-regulate immunoreactivity, thereby reducing T-lymphocyte function and, consequently, eosinophil activation. This effect may be dose-dependent, given that studies with lower doses of inhaled corticosteroids (even allowing
Other studies with BDP, however, reported significant decreases in CD3 + and CD4+
T-cells during 12 weeks of treatment, which were associated with significant improvement in airway responsiveness in patients with atopic asthma (7). It is interesting to speculate whether the absence of an effect on Tlymphocytes may explain continuing symptoms in some asthmatic patients despite inhaled corticosteroid therapy, since recent studies show that persistent T-cell activation is a prominent feature of severe asthma (21). Interestingly, Vrugt et al. allergens and exposure of afferent nerve endings. The release of sensory neuropeptides by such airway neurones is thought to contribute to ongoing inflammation, bronchoconstriction, microvascular leakage and secretion of mucus. Epithelial damage is probably mediated via the release of basic proteins from activated eosinophils and proteolytic enzymes from mast cells, leading to the release of a range of mediators, cytokines, chemokines and growth factors that act as chemoattractants, inhibit apoptosis of eosinophils and stimulate expression of cellular adhesion molecules. Maintenance of epithelial integrity and function therefore represents a target for anti-asthma therapy. There is evidence to suggest that inhaled corticosteroids reduce epithelial damage and shedding, as shown by a reduction in epithelial cell counts in bronchoalveolar lavage following treatment with inhaled corticosteroids (14,23). This has also been demonstrated in biopsy studies, in which 10 years of treatment with inhaled corticosteroids was associated with improvements in epithelial abnormalities (24).
AIRWAY REMODELLING
A large body of evidence supports the fact that asthma is a chronic inflammatory disorder of the airways involving release of mediators from both mast cells and eosinophils, and orchestrated by T-lymphocytes. A feature of the chronic inflammatory process in asthma is airway remodelling (25) which is characterized by extensive deposition of collagen beneath the sub-epithelial layer. Fibroblasts appear to play an important role in this thickening of the basement membrane (26) which, in conjunction with smooth muscle hypertrophy/hyperplasia, has been suggested to contribute towards persistent hyperresponsiveness and irreversible obstruction of the airways (27). Indeed, increased basement membrane thickness has been shown to be positively correlated with airway reactivity to methacholine and negatively correlated with forced expiratory volume in 1 set (FEVi) (26,28); however, Chu et al. showed no correlation between basement membrane thickness and asthma severity (29).
A number of studies have investigated whether inhaled corticosteroids can alter the thickness of the basement membrane. In a small group of patients with mild asthma, no alteration in thickness was seen after treatment with budesonide 200 ,ug for 4 weeks (13). Although the study by Trigg et al. suggested that treatment with BDP for 4 months reduced basement membrane thickness, this was measured using an antibody to a collagen component rather than by the conventional method of light or electron microscopy (6). Olivieri et al. have also suggested that fluticasone propionate may reduce basement membrane thickness, but differences in the baseline measurements of thickness between the treated and placebo groups confound interpretation of this study (12). Beneficial effects of an inhaled corticosteroid were reported by Laitinen et al. who showed that the thickness of the tenascin layer in the basement membrane of patients with seasonal asthma fell by 39% after treatment with budesonide for 4-6 weeks during the pollen season (30). More studies are needed before a definite effect of inhaled corticosteroids on basement membrane thickening can be proven.
Increased vascularity is another aspect of the structural remodelling that occurs during chronic inflammation of the airways (31) and may have several consequences for patients with asthma. The most notable is a possible effect on airway responsiveness, since a small increase in thickness of the airway wall (e.g. because of oedema and/or microvascular engorgement) may lead to pronounced narrowing of the airway lumen during smooth muscle contraction (32). As described above, inhaled corticosteroids potentially reduce airway remodelling although data pertaining to their effect on increased airway vascularity are limited. In one recent study, Orsida et al. (33) reported a significant increase in the density of vessels in the lamina propria of mildly asthmatic patients who were not receiving inhaled corticosteroids compared with non-asthmatic controls, and vessel density was strongly correlated with both lung function and hyperresponsiveness.
Interestingly, those patients being treated with an inhaled corticosteroid showed a decreased level of vascularity (versus those not on such treatment), and this effect showed a trend towards dose-dependency.
Reduction of airway wall vascularity may therefore contribute to the therapeutic efficacy of inhaled corticosteroids, particularly at high dosages. Further studies are clearly warranted to delineate the mechanism of this anti-angiogenic effect.
Conclusions
The range of anti-inflammatory properties demonstrated for inhaled corticosteroids in biopsy studies on asthmatic patients can be summarized as follows: reduction in numbers of mast cells (most pronounced in atopic patients); reduction in numbers and activation of eosinophils; reduction in numbers and function of T-lymphocytes (particulary CD4 + cells); improved epithelial morphology and reduction in epithelial cell activation, and some degree of reversal of airway remodelling.
The combination of activities has been shown consistently among different patient types and in a variety of study designs.
Overall, these findings indicate that inhaled corticosteroids have a broad spectrum of anti-inflammatory effects, which supports their use as first-line therapy for asthma. Further studies are required to investigate the mechanism of continued inflammation in severe asthma, and the effect of inhaled corticosteroids on structural changes in the airways and how these changes relate to chronic inflammation. 
